Starling Oncology STLN
NASDAQ STLN
$6.22 -0.11 (-1.66%)
At close: Oct 1, 2026 · 4:00 PM EDT

Starling Oncology (STLN) Non-Current Deffered Revenue (2020 - 2021)

Updated

Starling Oncology's Non-Current Deffered Revenue was $6.3 million in Q3 2021, unchanged from $6.3 million a year earlier and unchanged from the prior quarter.

Analysis

Starling Oncology (STLN) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

From Q1 2020 onward, Starling Oncology has reported Non-Current Deffered Revenue for 7 quarters.

  • Per Business Quant data, STLN's Non-Current Deffered Revenue in the three quarters before Q3 2021 was $6.3 million (Q2 2021), $6.3 million (Q1 2021) and $6.3 million (Q4 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 HCA Healthcare 93.06 Bn 92.50 Bn - -
2 Natera 59.36 Bn 55.04 Bn 485.19 Mn 16.07 Mn
3 Quest Diagnostics 25.72 Bn 24.15 Bn 1.03 Bn -
4 Labcorp Holdings 24.93 Bn 22.69 Bn 1.11 Bn -
5 Guardant Health 23.83 Bn 19.89 Bn 219.03 Mn -
6 Tenet Healthcare 20.58 Bn 11.72 Bn - -
7 Tempus AI 14.35 Bn 11.38 Bn 246.50 Mn 22.08 Mn
8 Encompass Health 11.99 Bn 12.46 Bn - -
9 BrightSpring Health Services 11.21 Bn 9.55 Bn 492.75 Mn -
10 Starling Oncology 634.96 Mn 502.37 Mn 27.17 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 6.30 Mn
Jun 30, 2021 6.30 Mn
Mar 31, 2021 6.30 Mn
Dec 31, 2020 6.30 Mn
Sep 30, 2020 6.30 Mn
Jun 30, 2020 6.30 Mn
Mar 31, 2020 6.30 Mn
API Access

Starling Oncology Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=STLN&period=max&api_key=YOUR_API_KEY